The Role of Antipsychotics and Mood Stabilizers in Preventing Sickness Absence Among Employed Individuals With Bipolar Disorder: A Nationwide Register‐Based Study
Acta Psychiatrica Scandinavica · 2025
DOI: 10.1111/acps.13806 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Psychiatrica Scandinavica, 2025. Verfasst von Minna Holm und 3 weiteren Autor:innen. Beteiligte Einrichtung: Mental Health Team, Finnish Institute for Health and Welfare, Helsinki, Finland. Hauptthemen laut MEDLINE: Bipolar Disorder, Antipsychotic Agents, Antimanic Agents, Sick Leave. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Research Council of Finland.
Abstract (Originalsprache)
Introduction
Medication use may significantly affect work ability in bipolar disorder, but this area has been largely overlooked in research. We aimed to investigate how specific mood stabilizer and antipsychotic agents are associated with the risk of sickness absence among employed individuals with bipolar disorder.
Methods
We identified a nationwide cohort of 22,408 employed individuals with bipolar disorder, including 10,000 first‐episode cases, and followed them from 2005 to 2018 through the nationwide administrative registers. The risk of sickness absence was analyzed using within‐individual Cox regression where each person serves as their own control to eliminate selection bias.
Results
In the whole cohort, the monotherapies of lithium (HR = 0.75, 95% CI = 0.66–0.84), valproate (HR = 0.77, 0.70–0.85), and lamotrigine (HR = 0.87, 0.80–0.95) were associated with a lower risk of sickness absence than nonuse of mood stabilizers. In contrast, pregabalin monotherapy was associated with an increased risk of sickness absence (HR = 1.63, 1.34–1.99). Of antipsychotics, olanzapine was associated with a lower risk of sickness absence (HR = 0.75, 0.66–0.86) than antipsychotic nonuse. In the first‐episode sample, lithium (HR = 0.51, 0.41–0.64), valproate (HR = 0.63, 0.52–0.75), lamotrigine (HR = 0.79, 0.68–0.91), and olanzapine (HR = 0.69, 0.54–0.87) monotherapies were associated with a lower hazard of sickness absence than nonuse.
Conclusions
Mood stabilizers including lithium, valproate, and lamotrigine, as well as olanzapine, of antipsychotics may reduce the risk of sickness absence, particularly, in first‐episode patients. These findings encourage the continuous use of these medications to support occupational functioning among people with bipolar disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mental Health Team, Finnish Institute for Health and Welfare, Helsinki, Finland.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
- Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland.
- Center for Psychiatry Research, Stockholm Region, Stockholm, Sweden.
- School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
ORCID-Profile: Minna Holm, Heidi Taipale
Förderung
- Research Council of Finland
Zitieren
APA
Holm, M., Tanskanen, A., Tiihonen, J., & Taipale, H. (2025). The Role of Antipsychotics and Mood Stabilizers in Preventing Sickness Absence Among Employed Individuals With Bipolar Disorder: A Nationwide Register‐Based Study. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.13806
Vancouver
Holm M, Tanskanen A, Tiihonen J, Taipale H. The Role of Antipsychotics and Mood Stabilizers in Preventing Sickness Absence Among Employed Individuals With Bipolar Disorder: A Nationwide Register‐Based Study. Acta Psychiatrica Scandinavica. 2025. doi:10.1111/acps.13806
BibTeX
@article{Holm2025,
author = {Holm, Minna and Tanskanen, Antti and Tiihonen, Jari and Taipale, Heidi},
title = {The Role of Antipsychotics and Mood Stabilizers in Preventing Sickness Absence Among Employed Individuals With Bipolar Disorder: A Nationwide Register‐Based Study},
journal = {Acta Psychiatrica Scandinavica},
year = {2025},
doi = {10.1111/acps.13806}
}
EUVIMED